NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics reported a significant reduction in its net loss for the first half of 2024 compared to the same period in 2023, with expenses dropping notably in research and development as well as general administrative costs. Despite this improvement, the company still faces a challenging financial situation with a shareholders’ deficit and liabilities surpassing its assets.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
